Sökning: onr:"swepub:oai:DiVA.org:uu-55174" > Pleural disease dur...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03194naa a2200385 4500 | |
001 | oai:DiVA.org:uu-55174 | |
003 | SwePub | |
008 | 081017s1997 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:1955275 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-551742 URI |
024 | 7 | a https://doi.org/10.1183/09031936.97.101227112 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19552752 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hillerdal, Gunnaru Karolinska Institutet4 aut |
245 | 1 0 | a Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos |
264 | c 1997-12-01 | |
264 | 1 | b European Respiratory Society (ERS),c 1997 |
338 | a print2 rdacarrier | |
520 | a Bromocriptine, which is used in the treatment of Parkinson's disease, can cause adverse pleuropulmonary reactions. Exposure to asbestos can result in similar lesions. Fifteen patients with former exposure to asbestos, who developed pleural fibrosis after treatment with bromocriptine, were observed independently in Sweden (11 patients) and Australia (four patients). The patients complained of malaise, often associated with weight loss, dyspnoea, and a disturbing cough. Laboratory values included increased erythrocyte sedimentation rate and a low haemoglobin level. Lung function tests showed a restrictive lung function defect. Chest radiographs showed bilateral pleural fibrosis, with small amounts of fluid in some cases. Soon after bromocriptine was withdrawn, the patients improved clinically, and the laboratory values returned to normal. However, in most cases, pleural fibrosis and a restrictive lung function defect persisted to some extent. In conclusion, in patients who develop pleuropulmonary fibrosis whilst being treated with bromocriptine, former exposure to asbestos should be investigated. Conversely, when pleural changes develop in a patient on bromocriptine and with prior exposure to asbestos, the possible causative role of the drug should be discussed. Special follow-up may be indicated when bromocriptine is planned in a patient with previous asbestos exposure, and if symptoms or signs of pleural fibrosis develop, bromocriptine withdrawal should be considered. | |
700 | 1 | a Lee, J4 aut |
700 | 1 | a Blomkvist, A4 aut |
700 | 1 | a Rask-Andersen, Annau Uppsala universitet,Arbets- och miljömedicin4 aut0 (Swepub:uu)annaraan |
700 | 1 | a Uddenfeldt, M4 aut |
700 | 1 | a Koyi, Hemin4 aut |
700 | 1 | a Rasmussen, Eu Uppsala universitet,Arbets- och miljömedicin4 aut |
710 | 2 | a Karolinska Institutetb Arbets- och miljömedicin4 org |
773 | 0 | t European Respiratory Journald : European Respiratory Society (ERS)g 10:12, s. 2711-2715q 10:12<2711-2715x 0903-1936x 1399-3003 |
856 | 4 | u http://erj.ersjournals.com/content/10/12/2711.full.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-55174 |
856 | 4 8 | u https://doi.org/10.1183/09031936.97.10122711 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1955275 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.